Regardless, our findings strongly suggest that the simultaneous inhibition of mTORC1 and MNK1/2 kinases, both targeting eIF4E activity, may prove highly efficacious in treatment of CTCL and, in all likelihood, many other malignancies. This evidence concerns the gene MKNK1 and primary cutaneous T-cell non-Hodgkin lymphoma.